OnKure Therapeutics, Inc.
NASDAQ:OKUR · NASDAQ Global Market
-$0.05 today
Vol 0.12M · Avg 0.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-105.9%
avg -8.1%
ROIC
-110.9%
avg -106.3%
ROA
-95.8%
avg -81.0%
Analysis
ROA is currently the strongest return metric at -95.8% versus its period average of -81.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nicholas A. Saccomano | President, Chief Executive Officer & Director | $858,000.00 | — | 67 | $110,000.00 | 0.80% |
Samuel Agresta | Chief Medical Officer | $640,600.00 | — | 53 | $110,000.00 | 0.80% |
Jason A. Leverone | Chief Financial Officer | $591,200.00 | — | 52 | $110,000.00 | 0.80% |
Isaac Manke | Senior VP of Business Development & Director | $60,497.00 | — | 49 | $20,583.00 | 0.15% |
James Blake | Senior Vice President of Computational Drug Discovery | — | — | — | — | — |
Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology | — | — | — | — | — |
Mark L. Boys | Senior Vice President of Discovery Chemistry | — | — | — | — | — |
Rogan Nunn | General Counsel & Secretary | — | — | — | — | — |
Roberta Alton | Senior Vice President of Clinical Operations | — | — | — | — | — |
Dylan Hartley | Chief Scientific Officer | — | — | 57 | $110,000.00 | 0.80% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$4,721.01
Net Sentiment
$4,721.01
Net selling
Most Active
Saccomano Nicholas A
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $4,721.01 over the last 12 months. That adds up to net selling of $4,721.01. Saccomano Nicholas A was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Mersana Therapeutics, Inc.
MRSN
$145.36M
PDS Biotechnology Corporation
NASDAQ:PDSB
$58.61M
Xilio Therapeutics, Inc.
NASDAQ:XLO
$54.64M
Kezar Life Sciences, Inc.
KZR
$53.86M
FibroGen, Inc.
FGEN
$36.69M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Actinium Pharmaceuticals, Inc.
ATNM
$31.69M
Barinthus Biotherapeutics plc
BRNS
$27.41M
CEL-SCI Corporation
CVM
$7.42M
Tempest Therapeutics, Inc.
TPST
$5.60M
Who manages OKUR?
OnKure Therapeutics, Inc. (OKUR) lists 10 active executives. The top listed executive is Isaac Manke, Senior VP of Business Development & Director.
Are OKUR insiders buying or selling?
Recent insider activity shows net buying of $23.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.